Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05260684
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 134
- Registration Number
- NCT05180825
- Locations
- 🇫🇷
Chu de Besancon, Besancon, France
🇫🇷CHU de REIMS, Reims, France
🇫🇷Groupe Hospitalier Pellegrin, Bordeaux, France
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- MelanomaPRO, Russia
- Target Recruit Count
- 500
- Registration Number
- NCT05171374
- Locations
- 🇷🇺
Republican Clinical Oncology Center of Chuvashia, Cheboksary, Chuvash Republic,, Russian Federation
🇷🇺GBUZ Yuzhno-Sakhalinsk oncologic dispensary, Yuzhno-Sakhalinsk, Russian Federation
🇷🇺Irkutsk Regional Oncological Dispensary, Irkutsk, Irkutsk Region, Russian Federation
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05159245
- Locations
- 🇫🇮
Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland
🇫🇮Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital OYS Cancer Center, Oulu, Finland
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05071183
- Locations
- 🇺🇸
Local Institution - 2107, Houston, Texas, United States
🇺🇸Local Institution - 2102, Virginia Beach, Virginia, United States
🇺🇸Local Institution - 2101, California City, California, United States
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT04967079
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 84
- Registration Number
- NCT04961619
- Locations
- 🇹🇷
Novartis Investigative Site, Kecioren Ankara, Turkey
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Anna Raciborska
- Target Recruit Count
- 12
- Registration Number
- NCT04943224
- Locations
- 🇵🇱
Mother and Child Institute, Warsaw, Mazovian, Poland
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT04940052
- Locations
- 🇺🇸
Northwestern University Med School, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇻🇳Novartis Investigative Site, Hanoi, Vietnam
Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Ruta Arays
- Target Recruit Count
- 15
- Registration Number
- NCT04903119
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸St. Luke's University Health Network, Easton, Pennsylvania, United States
🇺🇸Markey Cancer Center, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.